CCAFX
Price
$36.82
Change
-$1.12 (-2.95%)
Updated
Dec 18 closing price
FSMDX
Price
$34.42
Change
-$1.27 (-3.56%)
Updated
Dec 18 closing price
Ad is loading...

CCAFX vs FSMDX

Header iconCCAFX vs FSMDX Comparison
Open Charts CCAFX vs FSMDXBanner chart's image
Calvert Mid-Cap A
Price$36.82
Change-$1.12 (-2.95%)
VolumeN/A
CapitalizationN/A
Fidelity Mid Cap Index
Price$34.42
Change-$1.27 (-3.56%)
VolumeN/A
CapitalizationN/A
CCAFX vs FSMDX Comparison Chart
Loading...
View a ticker or compare two or three
VS
CCAFX vs. FSMDX commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CCAFX is a Hold and FSMDX is a Hold.

FUNDAMENTALS
Fundamentals
FSMDX has more cash in the bank: 39.6B vs. CCAFX (241M). FSMDX pays higher dividends than CCAFX: FSMDX (1.28) vs CCAFX (0.00). CCAFX was incepted earlier than FSMDX: CCAFX (30 years) vs FSMDX (13 years). CCAFX is a more actively managed with annual turnover of: 27.00 vs. FSMDX (9.00). FSMDX has a lower initial minimum investment than CCAFX: FSMDX (0) vs CCAFX (1000). FSMDX annual gain was more profitable for investors over the last year : 20.70 vs. CCAFX (9.74). FSMDX return over 5 years is better than : 57.26 vs. CCAFX (9.34).
CCAFXFSMDXCCAFX / FSMDX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence30 years13 years-
Gain YTD8.67519.21145%
Front LoadN/AN/A-
Min. Initial Investment10000-
Min. Initial Investment IRAN/AN/A-
Net Assets241M39.6B1%
Annual Yield % from dividends0.001.28-
Returns for 1 year9.7420.7047%
Returns for 3 years1.0519.145%
Returns for 5 years9.3457.2616%
Returns for 10 years13.78122.5311%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ASC11.220.13
+1.17%
ARDMORE SHIPPING Corp
SUM50.770.02
+0.04%
Summit Materials
NVO108.01-0.04
-0.04%
Novo-Nordisk A/S
MYGN13.82-0.30
-2.12%
Myriad Genetics
QNCX1.84-0.07
-3.66%
Quince Therapeutics